Pls like_老虎社区_美港股上老虎

Jncy
2021-10-22

Pls like

Novavax Faces 1 Major Risk Right Now. Should You Buy the Stock Anyway?

Novavax (NASDAQ:NVAX) started the coronavirus vaccine race as a favorite. The company's shares even

Novavax Faces 1 Major Risk Right Now. Should You Buy the Stock Anyway?

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":851613538,"tweetId":"851613538","gmtCreate":1634902061887,"gmtModify":1634902138766,"author":{"id":3584074223056401,"authorId":3584074223056401,"authorIdStr":"3584074223056401","name":"Jncy","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Pls like</p></body></html>","htmlText":"<html><head></head><body><p>Pls like</p></body></html>","text":"Pls like","highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/851613538","repostId":2177663497,"repostType":4,"repost":{"id":"2177663497","pubTimestamp":1634901730,"share":"https://www.laohu8.com/m/news/2177663497?lang=&edition=full","pubTime":"2021-10-22 19:22","market":"us","language":"en","title":"Novavax Faces 1 Major Risk Right Now. Should You Buy the Stock Anyway?","url":"https://stock-news.laohu8.com/highlight/detail?id=2177663497","media":"Motley Fool","summary":"Novavax (NASDAQ:NVAX) started the coronavirus vaccine race as a favorite. The company's shares even ","content":"<p><b>Novavax</b> (NASDAQ:NVAX) started the coronavirus vaccine race as a favorite. The company's shares even soared more than 2,700% last year. But the tide has turned for the biotech company. The problem? Manufacturing issues have delayed Novavax's submission for emergency authorization in the U.S. and other countries. As a result, the shares have given back a large percentage of this year's gain.</p>\n<p>But things worsened in recent days. A news report suggested Novavax's delays may not be over. The stock sank nearly 15% in one trading session. Even before that decline, the shares were trading below Wall Street's most pessimistic 12-month share price forecast.</p>\n<p>As you might be guessing right now, the biggest risk Novavax faces is this: missing its latest goal to apply for authorization in the U.S., Europe, and other areas by the end of the year. That kind of news could crush the stock. Does this mean you should flee Novavax shares -- or use recent declines as a buying opportunity?</p>\n<h2>U.K. and U.S. trial data</h2>\n<p>First, let's take a look at what's happened so far. Novavax reported positive data from a U.K. trial early this year -- and solid results from its U.S. trial a few months later. With data from both trials, Novavax aimed to file for emergency authorization in the second quarter.</p>\n<p>Then, in May, Novavax said it wouldn't make that deadline. That was due to raw materials shortages and other manufacturing issues. To win authorization, a company must demonstrate it can manufacture quality product at scale over time. At this point, Novavax said it would complete its regulatory submission in the third quarter.</p>\n<p>In the most recent earnings call, Novavax extended the deadline once again -- to the fourth quarter. The company said it was still working with third parties on some elements and completing the validation of its analytical methods.</p>\n<p>So that brings us to the latest news. This week, Politico, citing people familiar with the situation, reported more troubles: Novavax's testing method to ensure the purity of vaccine batches hasn't met regulators' expectations. These people told Politico the manufacturing and testing issues could delay authorization of Novavax's vaccine candidate until the end of 2022.</p>\n<h2>Novavax reconfirms timeline</h2>\n<p>In response, Novavax issued a statement reconfirming its regulatory timeline. The company says it's \"now routinely producing high-quality product at commercial scale at multiple sites across the world.\"</p>\n<p>Now, let's talk about risk. Do we put our confidence in Novavax and its management team? The company <i>has</i> postponed its filing goal more than once. It's not impossible that another delay might be on the horizon. So, this is a risk we have to face. It's clear that more delays would damage investors' confidence in the company -- even if Novavax is trying its hardest to get everything right. And the share price would suffer.</p>\n<p>But if Novavax files for authorization according to plan, the shares could skyrocket. And vaccine revenue down the road represents another catalyst for share performance. In an earnings call earlier this year, Novavax predicted billions of dollars in revenue over the four to six quarters ahead. That's huge for a company's first commercialized product.</p>\n<p>From today's level, Novavax stock could climb 91% in the coming 12 months, according to Wall Street's average forecast. And if it meets its goals, it could move much higher over the longer term.</p>\n<p>Speaking of the long term, Novavax has a lot to offer down the road. The company's flu vaccine candidate -- NanoFlu -- met primary endpoints in its pivotal trial. The next step is a regulatory submission. And Novavax has launched a clinical trial of a combined COVID/flu vaccine. So far, it's ahead of rivals on that potential product.</p>\n<p>Of course, all of that sounds great. But to be successful in today's or future projects, it's critical that Novavax resolve any manufacturing and testing issues. They are key to gaining the regulatory nod -- and eventually selling products.</p>\n<h2>Should you buy Novavax?</h2>\n<p>So, should you flee Novavax or buy the shares? It all depends on your investing style. If you're a cautious investor, you probably should avoid Novavax shares right now. If Novavax disappoints investors again, the shares likely will tumble. And if the timeline to commercialization is long, the stock may take quite a while to recover.</p>\n<p>That said, if you're an aggressive investor, this could be a buying opportunity. Novavax still has what it takes to win in coronavirus and flu prevention down the road. I'm optimistic that it eventually will work out manufacturing problems. So, if you're willing to go through potential ups and downs in the meantime, now might be a good time to get in on this biotech stock.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Faces 1 Major Risk Right Now. Should You Buy the Stock Anyway?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Faces 1 Major Risk Right Now. Should You Buy the Stock Anyway?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-22 19:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/22/novavax-faces-1-major-risk-should-you-buy-anyway/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax (NASDAQ:NVAX) started the coronavirus vaccine race as a favorite. The company's shares even soared more than 2,700% last year. But the tide has turned for the biotech company. The problem? ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/22/novavax-faces-1-major-risk-should-you-buy-anyway/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/10/22/novavax-faces-1-major-risk-should-you-buy-anyway/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2177663497","content_text":"Novavax (NASDAQ:NVAX) started the coronavirus vaccine race as a favorite. The company's shares even soared more than 2,700% last year. But the tide has turned for the biotech company. The problem? Manufacturing issues have delayed Novavax's submission for emergency authorization in the U.S. and other countries. As a result, the shares have given back a large percentage of this year's gain.\nBut things worsened in recent days. A news report suggested Novavax's delays may not be over. The stock sank nearly 15% in one trading session. Even before that decline, the shares were trading below Wall Street's most pessimistic 12-month share price forecast.\nAs you might be guessing right now, the biggest risk Novavax faces is this: missing its latest goal to apply for authorization in the U.S., Europe, and other areas by the end of the year. That kind of news could crush the stock. Does this mean you should flee Novavax shares -- or use recent declines as a buying opportunity?\nU.K. and U.S. trial data\nFirst, let's take a look at what's happened so far. Novavax reported positive data from a U.K. trial early this year -- and solid results from its U.S. trial a few months later. With data from both trials, Novavax aimed to file for emergency authorization in the second quarter.\nThen, in May, Novavax said it wouldn't make that deadline. That was due to raw materials shortages and other manufacturing issues. To win authorization, a company must demonstrate it can manufacture quality product at scale over time. At this point, Novavax said it would complete its regulatory submission in the third quarter.\nIn the most recent earnings call, Novavax extended the deadline once again -- to the fourth quarter. The company said it was still working with third parties on some elements and completing the validation of its analytical methods.\nSo that brings us to the latest news. This week, Politico, citing people familiar with the situation, reported more troubles: Novavax's testing method to ensure the purity of vaccine batches hasn't met regulators' expectations. These people told Politico the manufacturing and testing issues could delay authorization of Novavax's vaccine candidate until the end of 2022.\nNovavax reconfirms timeline\nIn response, Novavax issued a statement reconfirming its regulatory timeline. The company says it's \"now routinely producing high-quality product at commercial scale at multiple sites across the world.\"\nNow, let's talk about risk. Do we put our confidence in Novavax and its management team? The company has postponed its filing goal more than once. It's not impossible that another delay might be on the horizon. So, this is a risk we have to face. It's clear that more delays would damage investors' confidence in the company -- even if Novavax is trying its hardest to get everything right. And the share price would suffer.\nBut if Novavax files for authorization according to plan, the shares could skyrocket. And vaccine revenue down the road represents another catalyst for share performance. In an earnings call earlier this year, Novavax predicted billions of dollars in revenue over the four to six quarters ahead. That's huge for a company's first commercialized product.\nFrom today's level, Novavax stock could climb 91% in the coming 12 months, according to Wall Street's average forecast. And if it meets its goals, it could move much higher over the longer term.\nSpeaking of the long term, Novavax has a lot to offer down the road. The company's flu vaccine candidate -- NanoFlu -- met primary endpoints in its pivotal trial. The next step is a regulatory submission. And Novavax has launched a clinical trial of a combined COVID/flu vaccine. So far, it's ahead of rivals on that potential product.\nOf course, all of that sounds great. But to be successful in today's or future projects, it's critical that Novavax resolve any manufacturing and testing issues. They are key to gaining the regulatory nod -- and eventually selling products.\nShould you buy Novavax?\nSo, should you flee Novavax or buy the shares? It all depends on your investing style. If you're a cautious investor, you probably should avoid Novavax shares right now. If Novavax disappoints investors again, the shares likely will tumble. And if the timeline to commercialization is long, the stock may take quite a while to recover.\nThat said, if you're an aggressive investor, this could be a buying opportunity. Novavax still has what it takes to win in coronavirus and flu prevention down the road. I'm optimistic that it eventually will work out manufacturing problems. So, if you're willing to go through potential ups and downs in the meantime, now might be a good time to get in on this biotech stock.","news_type":1},"isVote":1,"tweetType":1,"viewCount":430,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Novavax Faces 1 Major Risk Right Now. Should You Buy the Stock Anyway?

评论（2）

热议股票